Clinical Drug Experience Knowledgebase

Adenocarcinoma (Phase 2)

Adrenocortical Carcinoma (Phase 2)

Astrocytoma (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Islet Cell (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colonic Neoplasms (Phase 2)

Ependymoma (Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 3)

Head and Neck Neoplasms (Phase 2)

Intestinal Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Meningioma (Phase 2)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neurilemmoma (Phase 2)

Neuroblastoma (Phase 2)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Neuroendocrine Tumors (Phase 2)

Neurofibroma (Phase 2)

Neurofibromatoses (Phase 2)

Oligodendroglioma (Phase 2)

Optic Nerve Glioma (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pituitary Diseases (Phase 2)

Pituitary Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Rhabdoid Tumor (Phase 2)

Sarcoma (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Vulvar Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)